FDA highlights new tech to monitor trials

The FDA is encouraging drug developers to turn to new technology to help them monitor clinical trial work without resorting to frequent site visits, according to a report in Outsourcing-Pharma. In a new set of proposed guidelines, regulators specifically cited electronic data capture and statistical assessments to help them monitor the quality of the studies they sponsor. But no company, regulators add, should call a halt to their on-site visits. Story

Suggested Articles

Bausch Health is paying $10 million upfront for the option to acquire Allegro Ophthalmics’ eye disease assets, with a promise of $40 million to come.

Anthony Coyle, Ph.D., has signed up to run Repertoire Immune Medicines’ R&D.

The IPO haul will set Kronos up to start a registrational phase 2/3 trial of a first-line AML drug licensed from Bischofberger's former employer.